-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25

Benzinga·06/17/2026 14:00:01
Listen to the news
TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $1.5 to $1.25.